Nanoparticle D20 Tag Targeting Inflamed Tissues
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for targeting neutrophils in acute inflammatory disorders, such as acute respiratory distress syndrome (ARDS), are limited due to the adverse effects of antibodies on neutrophil function and the inability of nanoparticles to effectively concentrate in inflamed tissues without relying on antibody-based targeting.
Innovation Solution
Development of nanoparticle compositions, including liposomes and lipid nanoparticles, conjugated with a D20 tag comprising dibenzocyclooctyne (DBCO) covalently attached to proteins, which allows for specific targeting and accumulation in inflamed tissues independent of antibodies, enhancing drug delivery to neutrophils and other leukocytes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If antibodies against neutrophil markers (e.g., Ly6G) are used for targeting, then neutrophil targeting is achieved, but neutrophil function is dramatically affected
Solution Approach 1:
The patent uses denatured protein nanoparticles as an intermediary carrier that indirectly targets neutrophils through non-specific protein uptake mechanisms rather than direct antibody binding. This intermediary approach allows neutrophil targeting without the harmful effects of antibody-mediated functional impairment
Solution Approach 2:
The patent replaces the biological targeting mechanism (antibody-protein interaction) with a physical/chemical mechanism (denatured protein nanoparticle uptake). This substitution eliminates the need for antibody binding while achieving similar targeting effects through passive accumulation in inflamed tissues
2Productivity
If nanoparticle structure engineering is performed to improve biodistribution, then pharmacokinetics are improved, but the complexity of nanoparticle design increases
Solution Approach 1:
The patent modifies nanoparticle parameters (protein denaturation state, nanoparticle size, surface charge) to optimize biodistribution and neutrophil targeting. By systematically changing these parameters, the patent achieves improved drug delivery without requiring complex multi-component designs
Solution Approach 2:
The patent applies local quality modifications by creating denatured protein nanoparticles with specific local structural characteristics (aggregated protein structure) that enhance neutrophil uptake. This localized structural feature provides targeting capability without requiring complex overall nanoparticle architecture
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoparticle compositions effectively concentrate in inflamed tissues, reducing neutrophil-mediated inflammation and edema, and can deliver drugs directly to the lung vasculature, providing therapeutic benefits in conditions like ARDS without the side effects associated with antibody targeting.
Implementation Method 1
The D20 tag comprises dibenzocyclooctyne (DBCO) covalently attached to a protein
Data Source
AI summary
Provided herein are compositions comprising a nanoparticle and a D20 tag. The D20 tag comprises dibenzocyclooctyne (DBCO) covalently attached to a protein. Also provided are diagnostic and therapeutic methods utilizing the nanoparticle composition.